A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To explore molecular biomarkers and/or gene expression signatures that predict response to
bevacizumab given in combination with paclitaxel as first line therapy in HER2 negative
metastatic breast cancer (MBC).